Performance of automated measurement of antibodies to cyclic citrullinated peptide in the routine clinical laboratory

References

• Epidemiology of the rheumatic diseases, A. J Silman, M. C Horchberg. Oxford Medical Publications, Oxford 1993; 7–68
   Google Scholar
• Nakamura R. M. Progress in the use of biochemical and biological markers for evaluation of rheumatoid arthritis. J Clin Lab Anal 2000; 14: 305–13
   PubMed Web of Science ®Google Scholar
• van Boekel M. A. M., Vossenaar E. R., van den Hoogen F. H. J., van Venrooij W. J. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 2002; 4: 87–93
   PubMedGoogle Scholar
• Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24
   PubMed Web of Science ®Google Scholar
• Sebbag M., Simon M., Vincent C., Masson‐Bessiere C., Girbal E., Durieux J. J., et al. The antiperinuclear factor and the so‐called antikeratin antibodies are the same rheumatoid arthritis‐specific autoantibodies. J Clin Invest 1995; 95: 2672–9
   PubMed Web of Science ®Google Scholar
• Schellekens G. A., de Jong B. A. W., van den Hoogen F. H. J., van de Putte L. B. A., van Venrooij W. J. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis‐specific auto‐antibodies. J Clin Invest 1998; 101: 273–81
   PubMed Web of Science ®Google Scholar
• van Jaarsveld C. H. M., ter Borg E. J., Jacobs J. W. G., Schellekens G. A., Gmelig‐Meyling F. H. J., van Booma‐Frankfort C., et al. The prognostic value of the antiperinuclear factor; anti citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol 1999; 17: 689–97
   PubMed Web of Science ®Google Scholar
• Schellekens A. G., Visser H., de Jong B. A. W., van den Hoogen F. H. J., Hazes J. M. W., Breedveld F. C., et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43: 155–63
   PubMed Web of Science ®Google Scholar
• Bizzaro M., Mazzanti., G., Tonutti E., Villalta D., Tozzoli R. Diagnostic accuracy of the anti‐citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001; 47: 1089–93
   PubMed Web of Science ®Google Scholar
• Kroot E. J. J. A., de Jong B. A. W., van Leeuwen M. A., Swinkels H., van den Hoogen F. H. J., van ‘t Hof M., et al. The prognostic value of anti‐cyclic citrullinated peptide antibody in patients with recent‐onset rheumatoid arthritis. Arthritis Rheum 2000; 43: 1831–5
   PubMed Web of Science ®Google Scholar
• Suzuki K., Sawada T., Murakami A., Matsui T., Tohma S., Nakazono K., et al. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol 2003; 32: 197–204
   PubMed Web of Science ®Google Scholar
• Lee D. M., Schur P. H. Clinical utility of the anti‐CCP assay in patients with rheumatic diseases. Ann Rheum Dis 2003; 62: 870–4
   PubMed Web of Science ®Google Scholar
• De Rycke L., Peene I., Hoffman I. E. A., Kruithof E., Union A., Meheus L., et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra‐articular manifestations. Ann Rheum Dis 2004; 63: 1587–93
   PubMed Web of Science ®Google Scholar
• Pinheiro G. C., Scheinberg M. A., Aparecida da Silva M. Anti‐cyclic citrullinated peptide antibodies in advanced rheumatoid arthritis. Ann Intern Med 2003; 139: 234–5
   PubMedGoogle Scholar
• van Venrooij W. J., van Boekel M. A. M., van den Hoogen F. H. J., Drijfhout J. W. 2de generatie anti‐CCP test voor de vroege detectie van reumatoïde artritis. Ned T Rheum 2002; 2: 6–10
   Google Scholar
• Visser H., le Cessie S., Vos K., Breedveld F. C., Hazes J. M. W. How to diagnose rheumatoid arthritis early. A predictive model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46: 357–65
   PubMed Web of Science ®Google Scholar
• Zweig M. H., Campbell G. Receiver‐operating characteristics (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39: 561–77
   PubMed Web of Science ®Google Scholar
• Waaler E. On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. Acta Pathol Microbiol Scand 1940; 17: 172–88
   Google Scholar
• Rose H. M., Ragan C., Pearce E., Lipman M. O. Differential agglutination of normal and sensitized sheep erythrocytes by sera of patients with rheumatoid arthritis. Proc Soc Exp Biol Med 1949; 68: 1–6
   Web of Science ®Google Scholar
• Girbal‐Neuhauser E., Durieux J‐J., Arnaud M., Dalbon P., Sebbag M., Vincent C., et al. The epitopes targeted by the rheumatoid arthritis‐associated antifillagrin auto‐antibodies are posttranslationally generated on various sites of (pro)fillagrin by deimination of arginine. residues. J Immunol 1999; 162: 585–94
   PubMed Web of Science ®Google Scholar
• Mediwake R., Isenberg D. A., Schellekens G. A., van Venrooij W. J. Use of anti‐citrullinated peptide and anti‐RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 2001; 60: 67–8
   PubMed Web of Science ®Google Scholar
• Hoffman I. E. A., Peene I., Cebecauer L., Isenberg D., Huizinga T. W. J., Union A., et al. Presence of rheumatoid factor and antibodies to citrullinated peptides in systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 330–2
   PubMedGoogle Scholar